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PENILAIAN KEKANGAN PENDIDIKAN DAN EKONOMI TERHADAP 
PELAKSANAAN KONSEP UBAT PERLU DI MALAYSIA 
 
ABSTRAK 
Walaupun senarai Ubat Perlu Kebangsaan (NEML) di Malaysia telah 
dilancarkan pada tahun 2000, tidak terdapat sebarang kajian yang telah dijalankan 
untuk mengukur tahap kesedaran terhadap konsep ubat perlu di kalangan pengamal 
perubatan, ahli farmasi dan pelajar-pelajar perubatan dan farmasi, atau untuk 
mengukur tahap keupayaan membeli ubat untuk rawatan penyakit kronik.  Kajian ini 
mengandungi tiga bahagian.  Bahagian pertama mengenal pasti pengetahuan, tingkah 
laku dan praktis pengamal perubatan dan ahli farmasi masing-masing di klinik dan 
hospital kerajaan.  Dua soal selidik yang berasingan telah digunakan.  Soal selidik 
telah dipos ke 113 klinik dan 60 hospital di Semenanjung Malaysia.  Daripada 
bilangan tersebut, 186 pengamal perubatan (65 klinik) dan 277 ahli farmasi (44 
hospital) telah memberikan respons kepada soal selidik tersebut.  Nilai median 
pengetahuan adalah 5 bagi kedua-dua kumpulan daripada 8 poin; nilai skor median 
bagi tingkah laku adalah 17 dan 18 daripada 25 poin, manakala nilai skor median 
bagi praktis adalah 8 dan 6 daripada jumlah total 10 bagi kedua-dua pengamal 
perubatan dan ahli farmasi, masing-masing.  Bahagian kedua telah dijalankan untuk 
mengukur pengetahuan dan tingkah laku pelajar-pelajar perubatan dan farmasi di 
universiti-universiti kerajaan di Malaysia terhadap ubat perlu dan untuk menilai 
kurikulum universiti jika konsep ubat perlu diajar kepada pelajar-pelajar 
prasiswazah.  Soal selidik untuk pelajar dan kurikulum telah dipos ke 5 universiti.  
 xxv
Sejumlah 250 pelajar perubatan dan 314 pelajar farmasi telah melengkapkan soal 
selidik dengan memberikan kadar respons 60% dan 100% bagi fakulti perubatan dan 
farmasi setiap satu.  Nilai skor median bagi pengetahuan adalah 3 dan 4 daripada 8 
poin, manakala skor median bagi tingkah laku adalah 8 bagi kedua-dua kumpulan 
daripada 10 poin bagi pelajar perubatan dan farmasi setiap satu.  Bahagian ketiga 
telah dilaksanakan untuk menilai tahap keupayaan membeli ubat perlu bagi rawatan 
penyakit hipertensi, diabetes mellitus jenis II, asma dan kombinasi penyakit-penyakit 
kronik tersebut.  Kajian kes telah dijalankan untuk menilai kandungan preskripsi 
yang diperolehi daripada borang tuntutan klinik panel USM bagi tahun 2006.  Tahap 
keupayaan membeli ubat yang digunakan telah diukur menggunakan harga ubat 
daripada kedai farmasi.  Tahap keupayaan membeli dinilai sebagai bilangan hari gaji 
yang diperlukan untuk membiayai rawatan untuk tempoh satu bulan oleh staf USM 
yang berpendapatan paling rendah.  Tahap keupayaan membeli didapati rendah bagi 
kebanyakan produk-produk berjenama, bagi kebanyakan rawatan kombinasi dan 
rawatan bagi kes-kes penyakit berganda.  Justeru itu, usaha diperlukan di Malaysia 
untuk memfokus bagi meningkatkan kesedaran di kalangan profesional kesihatan 
terhadap konsep ubat perlu.  Komitmen kerajaan juga diperlukan untuk memenuhi 
keperluan rakyat yang mengalami penyakit kronik. 
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EVALUATION OF EDUCATION AND ECONOMIC BARRIERS IN 
IMPLEMENTATING ESSENTIAL MEDICINES CONCEPT IN MALAYSIA 
 
ABSTRACT 
Although the National Essential Medicines List (NEML) in Malaysia was 
launched in 2000, there were no studies conducted to measure prescribers, 
pharmacists and medical and pharmacy students’ awareness on essential medicines 
concept, or to measure affordability of actual prescriptions used for treatment of 
chronic conditions. This study consists of three parts. The first part determined 
knowledge, attitude and practice of prescribers and pharmacists among government 
clinics and hospitals, respectively. Two separate survey questionnaires were used. 
Questionnaires were mailed to 113 clinics and 60 hospitals in west Malaysia. Out of 
65 clinics (186 prescribers) and 44 hospitals (277 pharmacists) responded to the 
survey. Knowledge median scores were 5 for both groups; out of 8 points, attitude 
median scores were 17 and 18, out of 25 points, while practice median scores were 8 
and 6 out of 10 points for prescribers and pharmacists, respectively. The second part 
was conducted to measure knowledge and attitude of medical and pharmacy students 
on essential medicines in Malaysian government universities  and to check university 
curricula if essential medicines concept is taught to undergraduate students. The 
survey questionnaires for students’ and the curriculum survey were mailed to 5 
universities. A total of 250 medical students and 314 pharmacy students completed 
questionnaire for a valid response rate of 60% and 100% for medicine and pharmacy 
schools, respectively.  Knowledge median scores were 3 and 4 out of 8 points, while 
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attitude median scores were 8 of the two groups out of 10 points for medical and 
pharmacy students, respectively. The third part was conducted to evaluate 
affordability of essential medicines used in treatment of hypertension, diabetes type 
II, asthma and multiple chronic conditions of the previous diseases in Malaysia. A 
case study measured prescriptions contents of USM panel clinics’ claim forms for 
year 2006. Affordability of medicines used was calculated using private retail 
pharmacies prices. Affordability was expressed as number of days’ salary required 
by a USM lowest wage workers to pay for one month treatment. Low affordability 
was noted for most brands products, most combined treatments and all multiple 
chronic cases treatments. Therefore, efforts are required in Malaysia to focus on 
increasing the awareness of health professionals on essential medicines concept. A 
commitment by the government is also required to meet the needs of citizens who 
suffer from chronic diseases. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
1.1.1 Definition and general principles of essential medicines 
The principal idea of essential medicines list (EML) is that certain medicines 
have more importance than others in terms of priority for treating some diseases 
conditions (Chirac, 2003). The essential medicines concept could lead to better 
access to health care through enhanced medicine management and the use of efficient 
financial resources. Essential medicines are one of the key primary health care 
elements (Quick, 2003). 
According to the World Health Organization (WHO) “Essential medicines 
are those that satisfy the priority health care needs of the majority of the population. 
They are selected with due regard to public health relevance, evidence on efficacy 
and safety and comparative cost-effectiveness. Essential medicines (EM) are 
intended to be available within the context of functioning health systems at all times 
in adequate amounts, in the appropriate dosage forms, with assured quality and 
adequate information, and at a price the individual and the community can afford. 
The implementation of the concept of essential medicines is intended to be flexible 
and adaptable to many different situations; exactly which medicines are regarded as 
essential remains a national responsibility” (WHO, 2004).  
Essential medicines list is one of the key features of the national medicine 
policy and essential medicines program (Ratanawijitrasin et al., 2001). Key 
components of a national medicine policy contains many plans include; selection of 
essential medicines, affordability, medicine financing, supply system, medicine 
regulation, rational use of medicines, research, human resources development and 
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finally monitoring and evaluation. All components work together for better health 
care for the population (WHO, 2001a). 
WHO first formulated the concept of essential medicines in 1970, with 
definition of essential medicines (EM) in 1975 and publication of the first WHO 
model of essential medicines list in 1977 (WHO, 2004). The list contained 208 
generic medicines, which was easily adopted by any country based on the local 
situations and needs. The aim was to improve quality of health and make medicines 
affordable, available and improve their use (Dunne, 1996). WHO works with all 
countries to implement medicine policies and EML, and as a result over 150 
countries have an essential medicine list, three quarters of which were recently 
updated (Quick, 2003; WHO, 2004). Reidenberg and Walley (2004), mentioned that 
many rich countries applied the EML in order to improve health care and manage the 
cost of medicines, as EML maintains medicine affordability in the selection of EM. 
  
1.1.2 Essential medicines concept  
 The reasons for implementing the concept of essential medicines are due to 
the following reason: (WHO, 2001a) 
• Essential medicines which are selected on the basis of safe and cost-effective 
clinical guidelines lead to more rational prescribing, and therefore lead to higher 
quality of health care and better value for money; 
• Training of health workers and medicine information in general can be more 
focused;  
• Prescribers gain more experience with fewer medicines and more easily 
recognize medicine interactions and adverse reactions;  
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• Quality assurance, procurement, storage, distribution and dispensing are all easier 
with a few number of medicines;  
• The procurement of fewer items in larger quantities results in more price 
competition and economies of scale. 
All these are even more important in resource-poor situation where the 
availability of medicines in the public sector is often not on regular basis. Under such 
circumstances, measures which ensure supply of essential medicines would result in 
real health gains and in increased confidence in health services (WHO, 2003b).  
 
1.1.2 (a) Practical implications of essential medicines concept   
National essential medicines lists and national medicine formularies, together 
with clinical guidelines should serve as the basis for formal education and in-service 
training of healthcare professionals. In addition, they should also be used in public 
education about medicine use and serve as the main basis for public sector medicine 
procurement, distribution, as well as for medicine donations (Quick et al., 1997). 
Health insurance schemes often use a limited list of medicines, the cost of 
which they will reimburse. This is one of the most common applications of the 
principles of medicine selection in developed countries (Quick et al., 1997). In 
developing countries, health insurance is less widespread, but coverage is growing 
and schemes are generally based on reimbursement for essential medicines. In view 
of the rapidly rising costs of medicines in most countries, it can be safely stated that 
all forms of health insurance scheme would ultimately need one process of medicine 
selection or another. Essential medicines lists and teaching about the benefits of 
medicine selection could also be used to influence practices in the private sector, 
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through the basic training of medical students, and programmes of continuing 
medical education with universities and professional associations (WHO, 2001a).  
 
1.1.2 (b) Challenges facing essential medicines concept 
There may be opposition to the use of the essential medicines list. Prescribers 
may see it as placing some restrictions on their clinical freedom, while pharmacists 
may be worried about the financial implications. Manufacturers may have fears of 
their market being eroded, and consumers may think they are being offered second-
rate, cheap medicines. If these concerns are not addressed, the concept of selection 
and the use of an essential medicines list may not be accepted. This is the reason why 
medicine selection process should be consultative and also justifies why informing 
and educating those affected is important (Quick et al., 1997).  
 
1.1.2 (c) Barriers to implementing essential medicines concept 
According to Tetteh (2007), access to essential medicines reduces disease 
burden. However, lack of access to EM is still a wide spread problem worldwide 
(Laing et al., 2003). Many factors affect access to essential medicines and hinder the 
implementation of the essential medicines list (EML) and essential medicines 
concept (EMC) in many countries; these factors thus act as barriers to medicines 
reaching the public. These barriers are: 
 
i. Medicine availability 
Many people throughout the world cannot obtain the medicines they need 
because the medicines are not available (WHO, 2001a). In a book authored by 
Zafrullah Chowdhury (1995), developing countries’ population which account for 
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about 75% of the world population consume only about 14% of the medicine supply 
for the whole world, which indicates low availability. In addition, Chowdhury 
(1995), further mentioned that irrational medicine use is common due to the 
promotion of many brands even though in the developing countries the largest 
numbers of brands are found due to lack of developed regulatory systems and quality 
control mechanisms. Medicine availability is one of the main barriers preventing 
essential medicines from reaching the public in the poor countries (Pécoul et al., 
1999). Moreover, the major barrier in poor countries is the prevention of availability 
of the essential new medicines needed for treating diseases such as TB, multidrug 
resistant malaria, etc (Ruxin et al., 2005).  
 
ii. Economic barriers 
Lee et al., (2002), define affordability as free access to good and services 
without economic barriers. Therefore, high costs of medicines make medicines 
poorly accessible to the public even for important treatments in rich countries 
(Lopert et al., 2002), because high costs lead to affordability barrier to medicines 
(Tetteh, 2007). In the United States there is no regulatory mechanism to medicine 
prices, therefore one in every four elderly patients limit their medicine use because of 
high prices (Ellner, 2003). Economic barriers due to costs of treatment and fees for 
services make health care unaffordable to individuals. Medicine affordability affects 
all social groups in all countries, but the poor are the most affected (Shalev, 2004). 
Transnational companies (TNCs) market their medicines all over the world; 
some of the medicines may be of doubtful efficacy. However, TNCs have little or no 
concern regarding the usefulness of these medicines or about the serious adverse 
reaction they cause as they do about obtaining high profits, thus resulting in high 
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medicine prices (Chowdhury, 1995). Research and development (R&D) is an 
additional reason for high cost of medicines, although few therapeutic gains may be 
recorded especially in third world countries where there is poor medicine regulatory 
machinery (Chowdhury, 1995; Pécoul et al., 1999). In low income countries 
combined effects of taxes, duties, distribution costs and retail margins result in a final 
medicine price that is commonly more than double and sometimes 35 times the 
producer or importer prices (Quick, 2003). WHO (2001a) is concerned with this 
phenomena because this result in many people all over the world not being able to 
obtain the medicines they need because it becomes unaffordable. 
The problem of increasing medicine costs is not restricted to developing 
countries. As most of the cost increases may be due to the introduction of new 
medicines, medicines selection becomes important even for rich countries. 
Therefore, the concept of essential medicines is not that of the developing countries 
alone (Hogerzeil, 2004). 
 
iii. Education barriers 
Doctors see medicines as means of stopping illness and are often bothered 
that pharmaceutical industries’ concern is mainly for profits because of: 
• the economics of medicine production;  
• health care marketing strategies of medicine industries; and 
• high medicine costs and affordability.  
These are usually not apart of the medical education curriculum in many 
developed and third world countries. Therefore, this lack of knowledge can make 
doctors easily convinced by the marketing promotion of pharmaceutical companies 
about new medicines and by any hints regarding their clinical freedom restriction. 
 
 
7
Eventually, the patients are the apparent purchaser of medicine of choice of their 
medicine as prescribed by the doctors. Therefore, doctors must have knowledge and 
be aware of the pharmaceutical situation and essential medicines concepts (EMC) 
which allows them to prescribe medicines as a matter of priority (Chowdhury, 1995). 
 According to Laing et al., (2001), in most developing countries, regular 
education of healthcare professionals is minimal, with little incentives for 
participation in continuous education programmes for promotions rather than to 
improve the quality of health care. Therefore, the production of printed bulletins and 
pharmaceutical newsletters can help to increase healthcare professionals’ awareness 
of EMC. In addition, Ruxin et al., (2005), stated that human resources inadequacies 
such as decline in number of pharmacists and technicians are one of the major 
barriers for access to essential medicines. On the other hand, Quick (2003) 
mentioned that presently, at least 88 countries have introduced the essential 
medicines concept into the curricula of medical and pharmaceutical students. Many 
people all over the world cannot obtain the medicines they need because there are no 
trained personnel to prescribe (WHO, 2001a). 
Many countries frequently lack adequate supplies of medicines. The reason 
behind medicine shortages may indicate attitude and behavior of the government, 
prescribers and dispensers (WHO, 1988). Organized physicians have opposed EMC 
in many developing countries (Kanji and Hardon, 1992). Educational programs and 
strategies must be applied for health students, physicians, nurses and pharmacists to 
improve their attitudes and behaviors towards EMC (WHO, 1988). Knowledge and 
attitude of healthcare professionals are important factors for implementing specific 
concepts. Health professionals were prevented access to some medical use of 
medicines due to their attitudes and knowledge toward that medicine. An effort is 
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made to educate physicians and nurses about the principle of palliative care 
(Rajagopal and Joranson, 2007).  
Healthcare professionals (prescriber and dispenser) should provide essential 
medicines (EM) as a matter of priority, to help people to select their medicines 
between the thousands of promoted medicines. This improves the essential medicines 
list (EML) implementation by bridging the gap between the theory of essential 
medicines list document and the actual implementation in the field.  
 
iv. Patent regulations 
Patent is a property right granted by a sovereign state to a product that has not 
been previously disclosed else where in the world. Patent gives the owner the right to 
prevent others from making, using, offering for sale or selling the product for a 
period of 20 years (Lehman, 2003). 
Although developments in Intellectual Propriety law in the wake of WTO’s 
Doha Declaration affirmed the priority of public health over the protection of patents, 
it agreed that the 50 least developed member country are not obliged to implement 
the patent law for pharmaceuticals until January 1, 2016 (Lehman, 2003). The Doha 
declaration acknowledged the short sightedness of the TRIPS agreement rule 
mandating that member countries could break patent only in public health 
endogenously, in order to produce generic medicine for local markets. Therefore, 
developing countries without local industries producing medicines will limit access 
to essential medicines (Westerhaus and Castro, 2006), but access to patent generic 
medicine from other countries remain restricted. 
Patent is controlled by World Intellectual Property Organization (WIPO) and 
World Trade Organization (WTO). In case of WTO patent regulation are contained 
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in the agreement of Trade-Related Aspect of Intellectual Property Rights (TRIPS). 
Under the present intellectual property regulation a patent may protect the sale of 
medicines for as long as 35 years, putting those medicines out of reach of poor 
people because of high prices (WHO, 2006). Moreover, according to Chowdhury 
(1995), patents enable pharmaceutical industries to adopt high prices. A third of the 
world’s population’ lack of access to quality medicines is due to patent protection of 
many essential medicines. Stronger protection of patents through introduction of 
patent protection stronger than required under WTO rules, strong intellectual 
property protection (IPP) and strengthened global rules under TRIPS make 
medicines unavailable and not affordable to the public (Bale, 2004). WTO rules on 
TRIPS encourage pharmaceutical industries to put patents as priority over public 
health care concerns (McDonald, 2007). 
 Furthermore, to increase access of patients to essential medicines, the 
medicines should be made affordable because high prices of medicines put them 
beyond reach of the public even in rich countries. In addition, patents maintain 
medicines prices high, which far exceed their cost of innovation (Henry and Lexchin, 
2002). This means that TRIPS Agreement standards are a factor that limits access to 
medicines because it does not allow the availability of affordable medicines, due to 
reducing generic competition in the pharmaceutical market. Therefore, patent of 
pharmaceutical products does not only limit access to medicines but also elevates 
medicines prices (Cohen, 2006).  In addition, Quick (2003), noted that appropriate 
use of TRIPS by any country makes cost of new medicines more affordable by 
patients. 
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v. Technical barriers 
One of the barriers to access to essential medicines is technical barriers. 
These barriers include counterfeit medicines (Anonymous, 2002; Pécoul et al., 
1999), also, John Bell, President of the Commonwealth Pharmaceutical Association, 
mentioned other factors contributed as a technical barriers to access essential 
medicines such as in-effective distribution system, non-existent or corrupt regulatory 
procedures, absence of rational medicine use strategies and lack of 
pharmacovigilance (Anonymous, 2002).  
 
vi. Political barriers 
According to Ellner (2003), political resistances are mainly from 
pharmaceutical companies which worry or limit their incentives to innovation. In 
addition, patients may think that essential medicine list (EML) prevents them from 
access to new medicines and their unique needs for medicines. Kanji and Hardon, 
(1992), noted that pharmaceutical industries oppose EMC in many developing 
countries. Limited or no manufacturing to pharmaceutical products by a country is a 
barrier to access medicines to the population (Cohen, 2006). Many countries have 
frequently lacked adequate supplies of medicines. Reason behind medicine shortage 
may indicate attitude and behavior of consumers and the medicine industries (WHO, 
1988).  
There is great need for political commitment to make implementation of 
EMC a reality. Therefore, evaluation of these barriers helps to put all hands on check 
to understand the strengths as well as weaknesses. However, evaluation of these 
barriers help in updating EML in an evidence based approach rather than experience 
based. 
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The study focused only on education and economic barriers because they are 
major barriers, and there are problems reported about the two barriers. In addition 
medicines availability was investigated by two researchers in all different sectors all 
over the country (Saleh and Ibrahim, 2005; Babar et al., 2007). Also the three other 
barriers are relatively minor barriers.   
 
1.1.3 Promoting the essential medicines concept 
There have been lots of benefits recorded with the use of essential medicines 
list in the public sector. However, in most low- and middle-income countries, the 
majority of the people are treated with medicines from the private sector, paid for 
out-of-pocket. Often, these consumers are prescribed or dispensed as high-priced 
medicines, often in small quantities, rather than as therapeutic amounts of essential 
medicines. Promotion of non-essential medicines often results in over-treatment of 
mild illness, inadequate treatment of serious illnesses and overuse of antibiotics. 
Widespread prescription and sale of non-essential medicines means that households, 
especially poor households, are not getting the best health care value for their money 
and may ultimately not receive the treatment they need (WHO, 2001a).  
WHO vision that people all over the world should have access to essential 
medicines (EM) which they need medicines that are safe, effective, and of good 
quality and that the medicines are prescribed and used rationally. Access to EM 
especially for HIV/AIDS, tuberculosis (TB) and malaria are critical to global efforts 
by WHO to prevent millions of death each year, reduce peoples’ suffering and help 
reduce the diseases treatment cost on the poorest families. WHO estimates that over 
10.5 million lives per year could be saved by 2015, also boosting economic growth 
and social development by expanding access to existing interventions for infectious 
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diseases, maternal and child health, and no eradicating communicable diseases. 
Medicines’ cost is the second highest expenditure after staff salaries in many 
developing countries. It is also the second highest household expenditure after food 
(WHO, 2004). Health is fundamental human rights. Highest access to health care, 
which include access to EM is a prerequisite for realizing those rights. This means 
that essential medicines are a human right i.e. a part of the right to health (Hogerzeil 
et al., 2006). 
WHO goal is to help save lives and improve health by ensuring medicines 
quality, efficacy, safety and rational use of medicines including traditional 
medicines, and by promoting equitable and sustainable access to EM, particularly for 
the poor. EM save lives, reduces sufferings and improves health situations, but only 
if they are of good quality and safe, available at low prices and properly used. WHO 
(2004) further stated that in many countries today not all these conditions are being 
met. 
Essential medicines (EM) have a huge economic impact on countries and 
household in developing countries. Due to high prices, medicines account for 25% - 
70% of all health care expenditure, compared to less than 15% in most high income 
countries. For governments and NGOs providing primary health care, medicines are 
the largest expense after personnel costs. For households in low income countries, 
medicines represent 50% - 90% of out of pocket spending on health, yet in some 
countries less than half of people living in poor households receive all the medicines 
they need  for curing illnesses, with one third receiving none of the medicines they 
need (WHO, 2004). 
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The reasons behind higher access to essential medicines and those efforts that 
are needed to close the gap to access is attributable to fundamental economic, social 
and educational factors that directly affect the health sector (Quick, 2003). 
The main projects to improve the use of medicines is to establish procedures 
for developing and revising an essential medicine list (or hospital formulary) based 
on treatments of choice, and to encourage targeted, problem-based in-service 
educational programs by professional societies, universities and the Ministry of 
Health, and request for regular continuing education for the licensure of healthcare 
professionals (Laing et al., 2001). 
 
1.1.4 Advantages of essential medicines list 
Essential medicines play a crucial role in many aspects of health care. 
Limited list of essential medicines lead to easy procurement; efficient storage and 
distribution due to low stocks, and this may minimize medicines wastages; and 
assured quality and easy dispensing (WHO, 2003a). In addition, it is also helpful for 
prescribers in focusing on few medicines, which result in more experience, better 
recognition of adverse medicine reaction, more rational use as in case of Mexican 
EML, where the list is used as a good instrument for rationalization of medicine 
therapy (Kravzov and Altagracia, 1994). Also it focuses education efforts of patients 
to reduce confusion and increase adherence to treatment (Quick et al., 1997).  
Moreover, EML is an aid to the following: 
• Procurement, due to the bulk purchase of generic medicines which is often of 
lower cost than the brand;  
• It makes for competition between generic suppliers and leads to lowering of 
prices;  
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• Choice of specific medicines helps in possibility of lower medicines waste 
(Redenberg, 1996); and  
• EML also is used in medicine distribution and procurement and for the 
development of national formulary (NF) (Laing et al., 2001); 
Furthermore, EM enables health authorities and policy makers to ensure those 
medicines are available on all health care system levels; it helps people to choose 
their treatments between large numbers of promoted medicines; it also helps 
healthcare professionals to know medicines that must be prescribed and dispensed as 
a matter of priority (Chirac, 2003). As in the case of Mali where NDP aimed to make 
medicines more available while improving appropriate uses by rational prescribing 
(Maïga et al., 2003). The national essential medicine list shows public health 
priorities which help policy makers to know the country’s national priorities for 
public procurement and reimbursement and for training and educating healthcare 
professionals (Smith and Tickel, 2003). The most important is EM are those that are 
aimed at reducing morbidity and mortality in the developing countries (Pécoul et al., 
1999).  
 
1.1.5 Selection of essential medicines  
Essential medicines (EM) are one of the main basic principles of a national 
medicine policy because it helps to set all requirements of the pharmaceutical system 
(WHO, 1988). Medicine selection, preferably linked to national clinical guidelines is 
a crucial step in ensuring access to essential medicines and in promoting rational 
medicine use, because no public sector or health insurance system can afford to 
supply or reimburse all medicines that are available in the market (Hogerzeil, 2003). 
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The selection of essential medicines is a two-step process. Market approval of 
a pharmaceutical product is usually granted on the basis of efficacy, safety and 
quality and rarely in the comparison with other products already in the market or 
based on cost. The regulatory decision defines the availability of a medicine in the 
market. In addition to this, most public medicine procurement and insurance schemes 
have mechanisms to limit procurement or reimbursement of medicine costs. For 
these decisions, an evaluation process is necessary, based on a comparison between 
various medicine products and in considerations of value for money. This second 
step leads to a list of essential medicines. 
 
1.1.5 (a) Selection criteria 
The treatment recommended and the medicines selected depend on many 
factors such as; the pattern of diseases prevalence, treatment facilities, the training 
and experience of available personnel, financial resources and genetics, demographic 
and environmental factors. The type and number of essential medicines selected 
depends on the circumstances in which the medicines are to be used, but the selection 
should be based on the EMC and in particular, on the following criteria which are 
used by the WHO expert committee on the use of essential medicines, that only 
medicines for which sound and adequate evidence of efficacy and safety in a variety 
of settings is available should be selected. Relative cost-effectiveness is a major 
consideration in the choice of medicines. In comparing between medicines, the total 
cost of treatment - not only the unit cost of the medicine – must be considered. Also, 
it should be taken into account the treatment in relation to the savings (i.e. surgery 
and hospitalization) and be compared with its efficacy; in some cases, the choice 
may also be influenced by other factors such as pharmaco-kinetic properties or by 
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local considerations such as the availability of facilities for manufacturing or storage. 
Different rates of success of treatment are achieved as a result of improved patients’ 
compliance. Reduction of loss or wastage achieved by using more stable products; 
selection of pharmaceutical products and dosage form which provide the most 
favorable benefit / risk ratio; each medicine selected must be available in a form in 
which adequate quality, including bioavailability can be ensured; its stability under 
the expected condition of storage must be determined (WHO, 2001a; Quick et al., 
1997; WHO, 1988). 
Most essential medicines should be formulated as single compounds. Fixed-
ratio combination products are acceptable only when the dosage of each ingredient 
meets the requirements of a defined population group, and when the combination has 
a proven advantage over single compounds administered separately, in terms of 
therapeutic effect, safety or patient adherence to treatment (WHO, 2001a; Quick et 
al., 1997; WHO, 1988). 
Selection must be by medicines international nonproprietary (generic) name. 
If necessary, a cross-index of nonproprietary and proprietary names should be 
supplied to prescribers and dispensers (WHO, 1988). According to Loff (2003), the 
benefits of the use and selection of the few numbers of medicines is to improve 
medicine supply, more rational prescribing and medicines affordability by decreasing 
medicine prices through bulk purchase of generic medicines. The cost-benefit ratio is 
the major concern in selecting some medicines to be in the essential medicines list. In 
other words, selection of EM should be based on the list of pathogenic conditions 
and complaints and the treatment of choice for these conditions as in the standard 
treatment guidelines. Therefore, EML is the next step after forming standard 
treatment guidelines by any country. Manufactures should not be involved in the 
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decision making process of defining an EML to prevent conflicts of interest (Laing et 
al., 2001). 
 
1.1.5 (b) Committee for selection of essential medicines 
Committee for selection of the essential medicines includes a wide range of 
geographical and professional backgrounds, including clinical pharmacology, clinical 
medicine, international public health, guideline development methodology, 
systematic literature search methods, risk-assessment and cost-effectiveness analysis. 
Patient advocacy groups and representatives of the health care industry are invited to 
comment on the applications and draft recommendations, but are not invited to attend 
decision-making meetings of the Expert Committee (WHO, 2001b). 
 
1.1.6 Updating essential medicines list 
Essential medicines list (EML) update should be done by an expert advisory 
committee that consists of clinical pharmacologist and physicians. Updating takes 
into account new information on medicine efficacy, safety, risk-benefit and data 
about cost-effectiveness. In other words, updating is due to adapting changes in new 
medicines, new indications, new diseases, discovered adverse effects and 
development of resistance. The list of essential medicines should have to be updated 
every two years (Chirac and Laing, 2001; Chirac, 2003)  
 
1.1.7 Essential medicines for special cases 
1.1.7 (a) Essential medicines for children 
Essential medicines for children are those medicines for use by pediatric 
only. In the past FDA criteria for selection EM for children was that medicine 
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content used in therapy of neonates has therapeutic value document, data for dosage 
recommendation, therapeutic indication and toxicity; finally, current labeling for 
neonatal use must exist, then frequency of use, low therapeutics index, reports of 
serious toxicity of the medicine (Kauffman, 1999). According to Hogerzeil (2006), 
WHO is boosting EM for children which aims firstly for the prequalification of 
pediatric medicines for treating AIDS, TB and Malaria and secondly, ensures 
suitable pharmaceutical formulation for children for all childhood disease in the 
EML to help fill up the gap to access EM. For this purpose, UNICEF and WHO hope 
to make access to EM for children because many pharmaceutical industries do not 
want a progress to EM for children, so that there are no pediatrics formulation 
withdrawal of many pharmaceutical preparations for children from markets and no 
registration of these products in many countries. Moreover, many medicines are not 
in suitable formulations and there is no funding for children (Anonymous, 2006).  
 
1.1.7 (b) Essential medicines for rare diseases 
Orphan medicines are medicines for rare diseases or low prevalence disorder. 
Some developed countries developed this policy for individual patients with rare 
disorders, although WHO has not boosted the rare essential medicines yet, but it is in 
use in the United State of America and European Union (Stolk et al., 2006). 
Reidenberg (2006) noted that the orphan medicine is not an absolute essential 
medicine unless identified as “essential”. 
 
1.1.8 Implementation of Malaysian essential medicines list 
The initial idea for implementing national essential medicines list (NEML) in 
Malaysia was in 1996. The idea came from the fact that, there must be some 
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measures to obtain health care cost of medicines especially in the private health 
sectors in order to maintain this sector at an affordable level. Also one of the aims of 
implementing NEML was to maintain medicines prices (MOH, 2006a). 
     The Malaysian national essential medicines list was launched on January 
27, 2000; the list was developed in four years. Table 1.1 shows a chronology of 
major events before implementing the national essential medicine list.  
Table 1.1: Chronology of major events before implementing the national 
essential medicine list in Malaysia 
Date Event 
January 31st, 2000 Editorial Voice : Status Quo in medicine use 
January 30th, 2000 Essential medicines and telehealth 
January 27th, 2000 Launching Ceremony – National Medicine List 
December 5th, 
1999 
Profit takes priority over care 
August, 1999 Excerpt of MMA-PhAMA Dialogue Report on NEML 
March 22nd, 1999 National Essential Medicine List Seminar in Kuala Lumpur 
February 11st, 1999 6thMeeting of National Essential Medicine List in Kuala Lumpur
July 4th, 1998 Internal Circulation of Draft National Essential Medicine List 
July 2nd, 1998 5thMeeting of National Essential Medicine List in Kuala Lumpur
June 25th, 1998 Going Generic and Bringing Health to All 
September 5th, 
1997 
Seminar on Essential Medicines Concept – An International 
Perspective 
 
June 23rd, 1997 4thMeeting of National Essential Medicine List in Kuala Lumpur 
 
October 25th, 1996 3thMeeting of National Essential Medicine List in Kuala Lumpur
September 3rd, 
1996 
2thMeeting of National Essential Medicine List in Kuala Lumpur
April 22nd, 1996 Malaysian Pharmaceutical Society rejected a proposal 
supporting National Essential Medicines Lists at its 29th AGM 
held in Kuala Lumpur 
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 “Table 1.1 Continued” 
Date Event 
March 21st, 1996 Inaugural meeting on National Essential Medicines List in Kuala 
Lumpur 
March 2nd, 1996 National Essential medicines List hailed 
February 17th, 
1996 
Announcement by the Health Minister in the local press 
February 16th, 
1996 
Press Release : Medicine Prices in Malaysia (Excerpt of 
Proposal) 
 
Source: USM Poison Centre Archive 
 
The list was developed by the Ministry of Health together with the Malaysian 
Pharmaceutical Society, the Federation of Private Medical Practitioners, the 
Malaysian Medical Association, the Pharmaceutical Association of Malaysia, The 
Malaysian Organization of Pharmaceutical Industries, Universiti Kebangsaan and 
Universiti Sains Malaysia (Ritikos, 2000). 
The NEML was formulated using the Ministry of Health’s (MOH) Medicines 
List as a basis. The MOH Medicines List which was introduced in 1983 serves as the 
essential medicines list for the public healthcare sector. Every medicine in the list 
was classified according to the category of medical officer or healthcare provider 
allowed to prescribe it. The list is dynamic and is reviewed every 4 months by a 
panel consisting of specialists from the main disciplines and pharmacists (MOH, 
2006a). 
The committee for creating the National Essential Medicines List decided 
that the List shall consist of two parts. The first part called the Essential Medicines 
List contains all preparations needed for primary and secondary healthcare treatment 
commonly used by medical officers and paramedics in primary healthcare facilities. 
Several preparations used in tertiary care are included in order to be consistent with 
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WHO’s model of Essential Medicines List. This part contains 358 chemical entities 
and 605 preparations (MOH, 2006a). 
The second part called the supplementary List consists of medicines used by 
specialists for tertiary level treatment. This part contains 257 chemical entities and 
391 preparations. While government’s hospitals have used a list of 680 generic 
medicines since 1983, this is the first time such a list has been extended for private 
sector use. The Malaysian Health Minister Datuk Chua Jui Meng said ”the formation 
of the list expects to bring down the cost of medicines as well as the healthcare, 
because the prescription of generic medicines brought down the cost by 50 to 70 per 
cent as mentioned in WHO report” (Azhar, 2000). 
Committee for selection of NEML included representatives from various 
sectors such as relevant government agencies, professional bodies, universities and 
the pharmaceutical industry. Sub committees were set up to help in various aspects 
of the list (MOH, 2006a):  
• medicines list contents  
• medicines prices  
• medicine information 
• logistics  
Prices for all the medicines are provided in a separate book (Abdul Razak, 2000).  
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1.2 Problem statement 
1.2.1 Health professional awareness on essential medicines in the Western 
Pacific Region 
WHO reported that in the Western Pacific Region, health workers have 
misconceptions about the essential medicines concept. They think that essential 
medicines have low efficacy and quality, cheap and may not satisfy patients’ need. 
Moreover, healthcare professionals think that their clinical freedom may be restricted 
by adhering to the list of essential medicines (WHO, 2005). This misconception may 
be due to the fact that there is no education for professionals as well as students for 
the medicine policy and the concept of essential medicines; or could be due to their 
negative attitude toward essential medicines. Low awareness and acceptance of 
essential medicines concept can act as a barrier to implementing this concept in the 
country.  
 
1.2.2 Medicines affordability in Malaysia  
It is a fact that in Malaysia, there is no regulatory system for medicines 
prices. This justifies why many essential medicines used in treatments of many 
chronic diseases are not affordable. Furthermore, Malaysia depends on imports of 
medicines, although the essential medicines list enables the country to focus on 
becoming self-reliant where the generic equivalence of essential medicines can be 
manufactured and popularized to meet health needs for the majority of the people 
(Ibrahim and Bahri, 2003). According to Azhar (2006) in Malaysia imported 
medicines prices have rise by up to 28 per cent annually in the last 10 years, 
especially daily used medicines. In addition, Chowdhury (1995), reported that most 
medicines prices range from 10-293% higher than in Australia and the UK. In 
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addition, prices are not stable, which increases annually by 20.7% when the rate of 
inflation was 7%. 
A survey on these prices was done by (Babar et al., 2007), which showed 
median prices ratios for some medicines for innovator brand (IB), the most sold 
generic (MSG), and the lowest priced generic (LPG) for government procurement 
prices, private retail pharmacy, and dispensing doctor sector as shown below (Table 
1.2). 
Table 1.2: Medicines prices in different sectors comparing with international 
reference price 
Sectors IB MSG LPG 
Government purchase price 2.4 X 1.56 X 1.09 X 
Private retail pharmacies 16 X 6.89 X 6.57 X 
Dispensing doctor 15 X 7.5 X 7.5 X 
X=Times the international reference price 
In addition, the study finding shows that most medicines in private sector 
have higher prices than the public sector and international reference prices; those 
medicines include off-patent one’s. 
 High medicine prices justify why some medicines of chronic diseases are not 
affordable. Chronic diseases need treatment for a life time. Therefore, if patient 
cannot afford medicines, this could lead to more serious illnesses and complications. 
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1.3 Rationale of the study 
In Malaysia national EML was launched in January 2000, and there is no 
study has been conducted to look into this issues recorded to the implementation of 
the EMC. This study, as the first of its kind in Malaysia, it considered as an 
important contribution, especially because it provides baseline evidence to monitor 
changes regarding transitions toward essential medicines concept’ awareness among 
practitioner as well as future healthcare professionals. In addition, problems of 
medicines affordability are still reported after the launched of EMC, although the two 
studies were using hypothetical methodology regarding treatments. 
In the absence of data regarding to what extent practitioners and future health 
professionals know about the essential medicines concept, a survey based study is the 
most suitable methodological approach in our setting. Health workers included are 
prescribers, pharmacists, and the future health professionals such as medical students 
and pharmacy students, to ensure that students know about the concept of essential 
medicines before graduation, because there might be no time for them to know or to 
consider issues such as the concept of essential medicines after graduation. 
Awareness of practitioners and future health workers on the essential 
medicines concept is important because they help consumers to select their 
medicines between the thousands of promoted medicines and improve the 
implementation of the essential medicines concept by filling the gap between the 
theory of essential medicines and the actual implementation of the list. Their 
misconceptions act as a barrier to implement the concept of essential medicines.  
Although medicines are free of charge in the public sectors, but when it is not 
available, or prescription does not include all medicines for a month’s therapy to 
treat chronic diseases, patient would have to buy their medications from the private 
